IRIS
MOSCARELLA, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.502
AS - Asia 2.223
NA - Nord America 1.889
SA - Sud America 379
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 9.033
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.431
US - Stati Uniti d'America 1.853
SG - Singapore 795
CN - Cina 495
IE - Irlanda 409
VN - Vietnam 371
HK - Hong Kong 318
BR - Brasile 314
IT - Italia 162
DE - Germania 143
GB - Regno Unito 134
KR - Corea 89
IN - India 56
GR - Grecia 47
SE - Svezia 34
AR - Argentina 33
UA - Ucraina 30
FR - Francia 23
MX - Messico 23
AT - Austria 22
TR - Turchia 20
FI - Finlandia 18
BD - Bangladesh 17
ID - Indonesia 15
BE - Belgio 14
CA - Canada 9
EC - Ecuador 9
MA - Marocco 9
ZA - Sudafrica 9
CO - Colombia 7
IQ - Iraq 7
JP - Giappone 7
NL - Olanda 7
ES - Italia 6
KE - Kenya 6
PK - Pakistan 6
PL - Polonia 6
VE - Venezuela 5
EG - Egitto 4
LT - Lituania 4
CL - Cile 3
IL - Israele 3
NP - Nepal 3
PH - Filippine 3
UY - Uruguay 3
AM - Armenia 2
BY - Bielorussia 2
DK - Danimarca 2
HN - Honduras 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
PE - Perù 2
PY - Paraguay 2
SA - Arabia Saudita 2
TN - Tunisia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
MU - Mauritius 1
MY - Malesia 1
NG - Nigeria 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UG - Uganda 1
Totale 9.033
Salva come PNG Salva come JPEG
Città #
Moscow 1.222
Singapore 404
Dublin 403
San Jose 318
Hong Kong 315
Santa Clara 299
Chandler 212
New York 141
Ho Chi Minh City 129
Ashburn 97
Seoul 89
Hefei 84
Hanoi 72
Bremen 60
Princeton 58
Roxbury 56
Beijing 55
The Dalles 47
Medford 43
Jacksonville 42
Naples 33
Boardman 30
Bengaluru 29
Da Nang 27
Los Angeles 26
São Paulo 25
Des Moines 24
Dallas 23
Nuremberg 22
Falkenstein 18
Rio de Janeiro 18
Cambridge 15
Wilmington 15
Brussels 14
Haiphong 14
Jinan 14
Nanjing 14
Council Bluffs 11
Hyderabad 11
Caserta 10
Munich 10
Vienna 10
Ann Arbor 9
Brasília 9
Helsinki 9
Mexico City 9
Rome 9
Thái Nguyên 9
Aversa 8
Belo Horizonte 8
Biên Hòa 8
Guangzhou 8
Ninh Bình 8
Sivas 8
Zhengzhou 8
Hangzhou 7
Shenyang 7
Stockholm 7
Frankfurt am Main 6
Hebei 6
Hải Dương 6
Johannesburg 6
London 6
Nairobi 6
Orem 6
Shenzhen 6
Boston 5
Bến Tre 5
Can Tho 5
Changsha 5
Columbus 5
Curitiba 5
Dhaka 5
Ercolano 5
Guayaquil 5
Houston 5
Joinville 5
Milan 5
Paris 5
Tianjin 5
Woodbridge 5
Atlanta 4
Bologna 4
Bắc Ninh 4
Campinas 4
Casablanca 4
Chennai 4
Lappeenranta 4
Malang 4
Manchester 4
Nha Trang 4
Shanghai 4
Warsaw 4
Bari 3
Bogotá 3
Boone 3
Carapicuíba 3
Casier 3
Charlotte 3
Columbia 3
Totale 4.882
Salva come PNG Salva come JPEG
Nome #
Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy 166
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 162
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 161
Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. 155
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 155
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 151
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 148
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study) 145
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 145
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study 141
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 136
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 136
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 135
Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry) 134
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 131
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 129
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 127
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 124
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 122
Bioresorbable Vascular Scaffolds in In-Stent Restenosis 122
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 122
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 120
Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis 120
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 120
Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry 118
Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry 117
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 115
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 115
Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? 112
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. 111
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 109
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 107
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management 107
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 106
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 104
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 104
Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis 101
Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry 101
Severely calcified coronary artery lesions: focus on interventional management 100
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 100
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 99
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 99
Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry) 98
One-Year Clinical Outcomes After Unrestricted Implantation of Absorb Bioresorbable Scaffold (RAI Registry) 98
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 96
Alternative Approaches for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: The Call for a Personalized Treatment 95
Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial 94
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 93
null 93
QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial 90
One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry 90
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 87
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 87
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 86
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry 85
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 85
IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry 85
Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention 84
Latest STEMI treatment: a focus on current and upcoming devices 83
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 83
Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry 83
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 82
Methods to assess bioresorbable vascular scaffold devices behaviour after implantation 82
Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies 82
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial) 81
Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology 81
Sudden cardiac death after early-onset myocardial infarction: a multicentre longitudinal cohort study with a 20-year follow-up 80
Five-year clinical outcomes of STEMI patients treated with a pre-specified bioresorbable vascular scaffold implantation technique: Final results of the BVS STEMI STRATEGY-IT 80
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 80
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial 80
Sex-Related Differences in Long-Term Outcomes After Early-Onset Myocardial Infarction 79
Multi-step percutaneous treatment of post-myocardial infarction ventricular septal defects: A case report and review of literature 79
Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy 79
Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA) 76
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 76
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) 74
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 74
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation 72
In-stent restenosis because of nickel hypersensitivity: A bioresorbable solution? 70
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience 69
New percutaneous interventions in heart failure 69
How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection? 69
Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre registro absorb italiano (RAI registry) 69
Time for implementing high-sensitivity cardiac troponin assays in emergency departments in Italy 68
Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes 68
Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term 67
First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis 65
Letter regarding "hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI" 65
Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis 64
Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium 61
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 51
Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions 28
Antithrombotic therapy in complex percutaneous coronary intervention 25
Correction to: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI) (Cardiovascular Diabetology, (2024), 23, 1, (420), 10.1186/s12933-024-02504-8) 10
Prognostic Impact of Bleeding in Interventional Cardiology 9
Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial 8
Balloon-Expandable Myval Octacor Versus Self-Expanding Evolut PRO/PRO+ and Acurate Neo2: Short-Term Outcomes From Propensity-Matched Analysis 7
[GISE/ANMCO/SIC Consensus document on the implementation of the new recommendations for the use of coronary functional testing and intravascular imaging in coronary angioplasty for chronic coronary syndromes] 6
Totale 9.212
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.100
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 7 48 6
2021/2022385 5 0 0 17 121 9 5 31 8 27 28 134
2022/2023777 93 58 12 50 108 35 3 34 356 1 11 16
2023/2024465 20 8 9 11 99 137 27 0 3 17 21 113
2024/20251.293 2 21 5 49 194 156 190 122 165 199 118 72
2025/20265.941 215 282 334 329 486 3.212 332 333 251 167 0 0
Totale 9.212